C2H
メニュー
About C2H
Who we are
Members
Links
Access
What we do
Drug price setting
Necessity of evaluation
Concept of cost-effecitveness
Evaluation of costs
Evaluation of outcome
Example
Other countries (1)
Other countries (2)
Application in Japan
Roles of C2H
Results
Results (~2019.3)
Results (2019.4~)
Tools
Guideline and others
Related literatures
PBMs
AP-7D
Database
Abbreviations
Latest news
News
Events
Reports
For experts
For clinicians/citizens
Contact us
Japanese
search
New C2H Report: Luspatercept (Reblozyl)
Report of the cost-effectiveness evaluation on Luspatercept (Reblozyl) was released.
Report on Luspatercept (Reblozyl)